Extracellular Vesicles-Mediated Bio-Orthogonal Catalysis in Growing Tumors

Author:

Sancho-Albero Maria1234ORCID,Sebastian Victor1234ORCID,Perez-Lopez Ana M.5ORCID,Martin-Duque Pilar136ORCID,Unciti-Broceta Asier5ORCID,Santamaria Jesus1234ORCID

Affiliation:

1. Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Avda. San Juan Bosco, 13, 50009 Zaragoza, Spain

2. Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Campus Rio Ebro, Edificio I+D, C/Poeta Mariano Esquillor, s/n, 50018 Zaragoza, Spain

3. Networking Research Center in Biomaterials, Bioengineering and Nanomedicine (CIBERBBN), Instituto de Salud Carlos III, 28029 Madrid, Spain

4. Department of Chemical and Enviromental Engineering, University of Zaragoza, Campus Rio Ebro, C/María de Luna, 3, 50018 Zaragoza, Spain

5. Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh EH4 2XR, UK

6. Instituto de Salud Carlos III, 28222 Madrid, Spain

Abstract

Several studies have reported the successful use of bio-orthogonal catalyst nanoparticles (NPs) for cancer therapy. However, the delivery of the catalysts to the target tissues in vivo remains an unsolved challenge. The combination of catalytic NPs with extracellular vesicles (EVs) has been proposed as a promising approach to improve the delivery of therapeutic nanomaterials to the desired organs. In this study, we have developed a nanoscale bio-hybrid vector using a CO-mediated reduction at low temperature to generate ultrathin catalytic Pd nanosheets (PdNSs) as catalysts directly inside cancer-derived EVs. We have also compared their biodistribution with that of PEGylated PdNSs delivered by the EPR effect. Our results indicate that the accumulation of PdNSs in the tumour tissue was significantly higher when they were administered within the EVs compared to the PEGylated PdNSs. Conversely, the amount of Pd found in non-target organs (i.e., liver) was lowered. Once the Pd-based catalytic EVs were accumulated in the tumours, they enabled the activation of a paclitaxel prodrug demonstrating their ability to carry out bio-orthogonal uncaging chemistries in vivo for cancer therapy.

Funder

ERC Advanced Grant CADENCE

AECC

Fundación Ramón Areces

EPSRC

Publisher

MDPI AG

Reference60 articles.

1. IARC—International Agency for Research on Cancer (2024, January 20). Pieejams. Available online: https://www.iarc.fr.

2. Emerging paradigms in metastasis research;Singhal;J. Exp. Med.,2020

3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

4. Giri, P.M., Banerjee, A., and Layek, B. (2023). A Recent Review on Cancer Nanomedicine. Cancers, 15.

5. Cancer nanomedicine: Progress, challenges and opportunities;Shi;Nat. Rev. Cancer,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3